# AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

> **NCT00427349** · PHASE2 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group** · enrollment: 46 (actual)

## Conditions studied

- Gastrointestinal Carcinoid Tumor
- Islet Cell Tumor
- Neoplastic Syndrome

## Interventions

- **DRUG:** AMG 706
- **DRUG:** octreotide

## Key facts

- **NCT ID:** NCT00427349
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11-07
- **Primary completion:** 2014-10
- **Final completion:** 2015-04
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2023-07-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00427349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00427349, "AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00427349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*